Rabies

Infectious Disease·MeSH: Rabies

Prevalence

0.1 / 100K

19 drugs in development·7 companies·4 clinical trials

Drug Pipeline by Phase

Phase 3(13)

Drug	Company
booster vaccination	Prime Medicine, Inc. (PRME)
equine rabies immunoglobulins	Sanofi (SNY)
human diploid cell vaccine	Sanofi (SNY)
human rabies immunoglobulins	Sanofi (SNY)
purified inactivated rabies vaccine	Sanofi (SNY)
purified inactivated rabies vaccine - imovax rabies	Sanofi (SNY)
purified inactivated rabies vaccine - verorab	Sanofi (SNY)
purified vero rabies vaccine - serum free	Sanofi (SNY)
Purified vero rabies vaccine - serum free - VRVg-2	Sanofi (SNY)
purified vero rabies vaccine - serum free vrvg-2	Sanofi (SNY)
rabies immune globulin	Sanofi (SNY)
Sinovac rabies vaccine	Crinetics Pharmaceuticals, Inc. (CRNX)
vrvg-2	Sanofi (SNY)

Phase 2(4)

Drug	Company
human rabies immune globulin	GH Research PLC (GHRS)
human rabies immunoglobulin	CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. (CBPO)
rabies vaccine	CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. (CBPO)
recombinant human rabies virus monoclonal antibody	CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. (CBPO)

Unknown(1)

Drug	Company
zamerovimab	HCW Biologics Inc. (HCWB)

Phase 2/Phase 3(1)

Drug	Company
rabies vaccine	HWH International Inc. (HWH)

BioSniper tracks 19 drugs in development for Rabies across 7 companies.

There are 4 clinical trials targeting Rabies tracked by BioSniper.

The estimated prevalence of Rabies is approximately 0.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.